Cargando…
DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
The mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to display antiproliferative effects on a wide spectrum of tumors. In vitro studies demonstrated that everolimus inhibited pituitary neuroendocrine tumor (PitNET) cell growth in a subset of patients. Sensitivity to everolim...
Autores principales: | Mangili, Federica, Esposito, Emanuela, Treppiedi, Donatella, Catalano, Rosa, Marra, Giusy, Di Muro, Genesio, Barbieri, Anna Maria, Locatelli, Marco, Lania, Andrea G., Mangone, Alessandra, Spada, Anna, Arosio, Maura, Peverelli, Erika, Mantovani, Giovanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204243/ https://www.ncbi.nlm.nih.gov/pubmed/35721701 http://dx.doi.org/10.3389/fendo.2022.867822 |
Ejemplares similares
-
PMON171 DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Pituitary Neuroendocrine Tumoral Cells
por: Mangili, Federica, et al.
Publicado: (2022) -
A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
por: Di Muro, Genesio, et al.
Publicado: (2023) -
A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation
por: Mangili, Federica, et al.
Publicado: (2021) -
Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant
por: Treppiedi, Donatella, et al.
Publicado: (2021) -
TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 Infection
por: Treppiedi, Donatella, et al.
Publicado: (2022)